...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective
【24h】

Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective

机译：临床蛋白质组学：使用质谱和生物信息学方法发现癌症生物标志物-前列腺癌的观点

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Prostate cancer (PCa) is an intractable disease, where diagnosis and clinical prediction of the disease course and response to treatment is compromised by the lack of objective and robust biomarker assays. In late stage metastatic disease, treatment options are limited, although it is recognized that some patients may benefit from immunotherapy and in particular vaccine therapy. However, research into biomarkers that correlate with the clinical outcome of immunotherapy has lagged behind vaccine development. Thus, proteomic tools are increasingly being utilized for the discovery of biomarkers which will allow us to make clinical decisions about patient treatment at an earlier stage and should aid in shortening the development time for vaccines. In this review we will summarize the various proteomic platforms used to investigate new biomarkers in PCa for better patient diagnosis, prognosis, patient stratification, treatment monitoring and clinical surrogate endpoints. We will discuss method limitations and highlight the key areas of research required for understanding the etiology of PCa.
机译：前列腺癌（PCa）是一种顽固性疾病，由于缺乏客观而强大的生物标志物检测方法，因此疾病进程和对治疗的反应的诊断和临床预测受到影响。在晚期转移性疾病中，治疗选择受到限制，尽管人们认识到某些患者可能会受益于免疫疗法，尤其是疫苗疗法。但是，与免疫疗法的临床结果相关的生物标志物的研究落后于疫苗的开发。因此，蛋白质组学工具被越来越多地用于生物标志物的发现，这将使我们能够在较早阶段就患者治疗做出临床决策，并应有助于缩短疫苗的开发时间。在这篇综述中，我们将总结用于研究PCa中新生物标记物的各种蛋白质组学平台，以更好地进行患者诊断，预后，患者分层，治疗监测和临床替代终点。我们将讨论方法的局限性，并重点介绍理解PCa病因所需的关键研究领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号